Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Joe who wrote (1337)	7/22/1998 7:46:00 AM
From: admr	Read Replies (1) \| Respond to of 4140

The Dow Jones did'nt mention who he worked for but I'm told be might be with Hambrecht and Quist. There was a phone number with the release for Otesa Middleton 202-862-6654 the Dow Jones reporter, I'm sure she can assist you in finding Mr. Lachman. Actually, I'm trying to educate myself as to which laser and procedure will be the treatment of choice. It's quite amazing the difference of opinion noted on the different threads. It appears to me that the excimer laser by Visx and the snrs Holmium laser can achieve the desired results in hyperopia. The question is which is safer, easier, cheaper and with less complications. The Visx people talk about regression quite a bit when talking about snrs but I have not seen anything that proves that the desired end point is not reached. Clearly, the excimer laser is the more invasive procedure, appears to have more complications and side effects. It appears to be more costly to the patient and doctor. The dow jones release appears to be a heads up about the use of the excimer laser in hyperopic patients and not to expect too much. This seems to concur with Dr. MacFarland's comments and my understanding also. Ltk seems to be the best kept secret in opthalmology. Mr. Lachman and the whole Opthalmology community need to be educated as to Ltk not be mention Wall Street.